These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1084 related items for PubMed ID: 28436316

  • 1. First-in-man experience of self-expanding nitinol stents combined with drug-coated balloon in the treatment of femoropopliteal occlusive disease.
    Mwipatayi BP, Perera K, Daneshmand A, Daniel R, Wong J, Thomas SD, Burrows SA.
    Vascular; 2018 Feb; 26(1):3-11. PubMed ID: 28436316
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Twelve-Month Results From the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease.
    Müller-Hülsbeck S, Keirse K, Zeller T, Schroë H, Diaz-Cartelle J.
    J Endovasc Ther; 2016 Oct; 23(5):701-7. PubMed ID: 27193308
    [Abstract] [Full Text] [Related]

  • 4. PEACE I all-comers registry: patency evaluation after implantation of the 4-French Pulsar-18 self-expanding nitinol stent in femoropopliteal lesions.
    Lichtenberg M, Kolks O, Hailer B, Stahlhoff WF, Tiefenbacher C, Nolte-Ernsting C, Arjumand J, Wittenberg G.
    J Endovasc Ther; 2014 Jun; 21(3):373-80. PubMed ID: 24915584
    [Abstract] [Full Text] [Related]

  • 5. One-Year Outcomes of the Paclitaxel-Eluting, Self-Expanding Stentys Stent System in the Treatment of Infrapopliteal Lesions in Patients With Critical Limb Ischemia.
    Bosiers M, Callaert J, Keirse K, Hendriks JMH, Peeters P, Verbist J, Maene L, Beelen R, Deloose K.
    J Endovasc Ther; 2017 Jun; 24(3):311-316. PubMed ID: 28351310
    [Abstract] [Full Text] [Related]

  • 6. 1-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery Disease: Evidence From the SFA-Long Study.
    Micari A, Vadalà G, Castriota F, Liso A, Grattoni C, Russo P, Marchese A, Pantaleo P, Roscitano G, Cesana BM, Cremonesi A.
    JACC Cardiovasc Interv; 2016 May 09; 9(9):950-6. PubMed ID: 27151609
    [Abstract] [Full Text] [Related]

  • 7. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
    Kinstner CM, Lammer J, Willfort-Ehringer A, Matzek W, Gschwandtner M, Javor D, Funovics M, Schoder M, Koppensteiner R, Loewe C, Ristl R, Wolf F.
    JACC Cardiovasc Interv; 2016 Jul 11; 9(13):1386-92. PubMed ID: 27388828
    [Abstract] [Full Text] [Related]

  • 8. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
    Scheinert D, Schmidt A, Zeller T, Müller-Hülsbeck S, Sixt S, Schröder H, Weiss N, Ketelsen D, Ricke J, Steiner S, Rosenfield K.
    J Endovasc Ther; 2016 Jun 11; 23(3):409-16. PubMed ID: 27117972
    [Abstract] [Full Text] [Related]

  • 9. Comparison of drug-eluting balloon angioplasty with self-expanding interwoven nitinol stent deployment in patients with complex femoropopliteal lesions.
    Teymen B, Akturk S, Akturk U, Tdjani M.
    Vascular; 2018 Feb 11; 26(1):54-61. PubMed ID: 28708023
    [Abstract] [Full Text] [Related]

  • 10. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
    Tran K, Ullery BW, Kret MR, Lee JT.
    Ann Vasc Surg; 2017 Jan 11; 38():90-98. PubMed ID: 27554688
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial.
    Tepe G, Schroeder H, Albrecht T, Reimer P, Diehm N, Baeriswyl JL, Brechtel K, Speck U, Zeller T.
    J Endovasc Ther; 2020 Apr 11; 27(2):276-286. PubMed ID: 32096451
    [Abstract] [Full Text] [Related]

  • 17. Provisional Stenting Using the Zilver PTX Drug-Eluting Stent After Drug-Coated Balloon Angioplasty: Initial Experience From the Double Drug Dose "3D" Study.
    Fanelli F, Cannavale A, Citone M, Santoni M, Gazzetti M, Falcone GM, Miele V.
    J Endovasc Ther; 2020 Feb 11; 27(1):34-41. PubMed ID: 31637956
    [Abstract] [Full Text] [Related]

  • 18. The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protégé EverfLex NitInol STent SYstem II (DURABILITY II).
    Matsumura JS, Yamanouchi D, Goldstein JA, Pollock CW, Bosiers M, Schultz GA, Scheinert D, Rocha-Singh KJ.
    J Vasc Surg; 2013 Jul 11; 58(1):73-83.e1. PubMed ID: 23642924
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions.
    Zeller T, Rastan A, Macharzina R, Tepe G, Kaspar M, Chavarria J, Beschorner U, Schwarzwälder U, Schwarz T, Noory E.
    J Endovasc Ther; 2014 Jun 11; 21(3):359-68. PubMed ID: 24915582
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.